MYC and cholangiocarcinoma: c-Myc induction drives cholestatic liver injury and cholangiocarcinoma (CCA) in mice, and the induction of Maf proteins (MafG and c-Maf) contributes to cholestatic liver injury, whereas SAM administration could be protective [163].